Journal of Education and
Research in Nursing
Review

Agalsidase Alpha and Agalsidase Beta Effect in Fabry Disease

1.

Department of First and Emergency Aid, İstanbul Kent University Faculty of Health Services , İstanbul, Turkey

2.

Department of Nursing, Hakkari University Faculty of Health Sciences, Hakkari, Türkiye

3.

Department of Nursing, Cyprus Science University, Graduate Education and Research Institute, Kyrenia, TRNC

Journal of Education and Research in Nursing 2022; 19: 484-488
DOI: 10.5152/jern.2021.93357
Read: 87 Downloads: 49 Published: 01 December 2022

Rare diseases are a group of diseases caused by genetic mutations. Fabry disease is a lysosomal storage disease with a low incidence in society and is caused by the mutation of the GLA gene above the X chromosome. Enzyme replacement therapy and oral chaperone therapy constitute the treatment of the disease. The management of Fabry disease requires the collaboration of various multidisciplinary health professionals. Because Fabry disease is chronic and progressive, the primary role of the nurse is to provide management of symptoms and help the patient and family manage the disease, as well as administer and follow up treatment.

Cite this article as: Misyağcı NM, Haylı ÇM, Büyükgönenç LA. Agalsidase alpha and agalsidase beta effect in fabry disease. J Educ Res Nurs. 2022;19(4):484-488.

Files
EISSN 2757-9204